CA2874655C - Methods of regulating cannabinoid receptor activity-related disorders and diseases - Google Patents

Methods of regulating cannabinoid receptor activity-related disorders and diseases Download PDF

Info

Publication number
CA2874655C
CA2874655C CA2874655A CA2874655A CA2874655C CA 2874655 C CA2874655 C CA 2874655C CA 2874655 A CA2874655 A CA 2874655A CA 2874655 A CA2874655 A CA 2874655A CA 2874655 C CA2874655 C CA 2874655C
Authority
CA
Canada
Prior art keywords
mnf
receptor
cells
compound
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2874655A
Other languages
English (en)
French (fr)
Other versions
CA2874655A1 (en
Inventor
Irving W. Wainer
Michel Bernier
Rajib K. Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA2874655A1 publication Critical patent/CA2874655A1/en
Application granted granted Critical
Publication of CA2874655C publication Critical patent/CA2874655C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2874655A 2012-05-25 2013-05-23 Methods of regulating cannabinoid receptor activity-related disorders and diseases Active CA2874655C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651961P 2012-05-25 2012-05-25
US61/651,961 2012-05-25
US201361789629P 2013-03-15 2013-03-15
US61/789,629 2013-03-15
PCT/US2013/042457 WO2013177418A1 (en) 2012-05-25 2013-05-23 Methods of regulating cannabinoid receptor activity-related disorders and diseases

Publications (2)

Publication Number Publication Date
CA2874655A1 CA2874655A1 (en) 2013-11-28
CA2874655C true CA2874655C (en) 2020-11-03

Family

ID=48577922

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874655A Active CA2874655C (en) 2012-05-25 2013-05-23 Methods of regulating cannabinoid receptor activity-related disorders and diseases

Country Status (6)

Country Link
US (5) US20150157580A1 (enExample)
EP (1) EP2854855B1 (enExample)
JP (1) JP6130495B2 (enExample)
AU (1) AU2013266235B2 (enExample)
CA (1) CA2874655C (enExample)
WO (1) WO2013177418A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944726A1 (en) * 2014-04-03 2015-10-08 Mitchell Woods Pharmaceuticals, Inc. Methods of treating breast cancer
US20180042867A1 (en) * 2015-03-06 2018-02-15 Mitchell Woods Pharmaceuticals, Inc. Methods of treating cancer
BR112018006633A2 (en) * 2015-09-30 2018-10-23 Bird Rock Bio, Inc. antibodies that bind to human cannabinoid receptor 1 (cb1)
WO2017059268A1 (en) * 2015-10-01 2017-04-06 Mitchell Woods Pharmaceuticals, Inc. Methods of reducing chemoresistance and treating cancer
EP3684797A4 (en) 2017-09-19 2021-07-07 Cannametrix, LLC CELL BASED ASSAY FOR QUANTIFYING THE POWER AND EFFECTIVENESS OF CANNABINOIDS AND / OR TERPENOIDS, AND RELATED METHODS OF USE
US11487195B2 (en) 2018-04-26 2022-11-01 Wonder Vision Techno Laboratory Co., Ltd. Dome screen, dome screen projection apparatus, and method for fabricating the same
CN109942462B (zh) * 2019-03-06 2022-01-14 宏冠生物药业有限公司 一种盐酸班布特罗的合成工艺
JP7532754B2 (ja) * 2019-09-04 2024-08-14 株式会社ニコン 画像解析装置、細胞培養観察装置、画像解析方法、及びプログラム
GB202302225D0 (en) * 2023-02-16 2023-04-05 Atrogi Ab New medical uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0639186T3 (da) 1992-04-17 1999-12-13 Abbott Lab Taxolderivater
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
EP1595146B1 (en) * 2003-02-18 2008-04-23 AstraZeneca AB Screening assays for cannabinoid-ligand-type modulators of gpr55
KR101378067B1 (ko) 2006-08-10 2014-04-10 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 （ｒ,ｒ）―페노테롤 및 （ｒ,ｒ）―또는 （ｒ,ｓ）―페노테롤 유사체의 제조방법 및 이의 울혈성 심부전증 치료를 위한 용도
EP2515946B1 (en) * 2009-12-23 2019-05-22 The Board of Trustees of the University of Illionis Nanoconjugates and nanoconjugate formulations
EP2544676B1 (en) * 2010-03-10 2018-09-19 The United States of America, as represented by The Secretary, Department of Health and Human Services The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Also Published As

Publication number Publication date
JP6130495B2 (ja) 2017-05-17
US20210038540A1 (en) 2021-02-11
AU2013266235A1 (en) 2014-12-04
WO2013177418A1 (en) 2013-11-28
JP2015519347A (ja) 2015-07-09
US10485771B2 (en) 2019-11-26
US20160331702A1 (en) 2016-11-17
US20190000781A1 (en) 2019-01-03
US20150157580A1 (en) 2015-06-11
US20200030261A1 (en) 2020-01-30
US10772849B2 (en) 2020-09-15
EP2854855A1 (en) 2015-04-08
AU2013266235B2 (en) 2017-06-08
US11389415B2 (en) 2022-07-19
US10130593B2 (en) 2018-11-20
EP2854855B1 (en) 2016-04-27
CA2874655A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
US11389415B2 (en) Methods of regulating cannabinoid receptor activity-related disorders and diseases
US10925840B2 (en) Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
Cao et al. Synthesis and evaluation of WK-X-34 derivatives as P-glycoprotein (P-gp/ABCB1) inhibitors for reversing multidrug resistance
US20180042867A1 (en) Methods of treating cancer
US20180271808A1 (en) Methods of reducing chemoresistance and treating cancer
Si et al. Identification of a novel pyridine derivative with inhibitory activity against ovarian cancer progression in vivo and in vitro
US20190076379A1 (en) Methods of treating breast cancer
US20170172944A1 (en) Methods of treating melanoma
Elrehany et al. Investigation of anticancer mechanisms of a chalcone/xanthine hybrid in non-small cell lung cancer
WO2013019655A2 (en) Vimentin as a biomarker for the progression of myeloproliferative neoplasms
WO2018140923A1 (en) Methods of treating cancer
Zhao et al. A novel Quinazoline derivative exerts anti-tumor effects in non-small cell lung cancer through Wnt/β-catenin pathway inhibition
US9994515B2 (en) Aryl naphthyl methanone oxime(s) and process for preparation thereof
Lai Development of Small Molecules Blocking Glucose Transporter or Inhibiting HSP90 for the Therapy of Cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180316